动物模型在间充质干细胞治疗慢性肝病临床前研究的应用  

A review on the application of animal models in preclinical research of the treatment of liver diseases with mesenchymal stem cells

作　　者：付旭锋[1,2] 陈冰冰[1,3] 严亚萍[1,3] 王宏[1,3] 王峻峰[4] 郑冰蓉[2] 司维[1,3] 

机构地区：[1]昆明理工大学灵长类转化医学研究院,昆明650500 [2]云南大学医学院,昆明650091 [3]云南中科灵长类生物医学重点实验室,昆明650500 [4]云南省第一人民医院肝胆外科,昆明理工大学附属昆华医院,昆明650032

出　　处：《中国实验动物学报》2017年第1期102-106,共5页Acta Laboratorium Animalis Scientia Sinica

基　　金：国家重点研发计划项目(2016YFA0101400);国家重大科学研究计划重大科学问题目标导向项目(2012CBA01305);云南省中青年学术和技术带头人后备人才及云南省技术创新人才(2012HB040)

摘　　要：慢性肝病进一步发展为肝纤维化并导致肝硬化,此时除了器官移植外没有更为有效的治疗方法。然而器官缺乏的问题迫使人们寻找更为有效的治疗策略。间充质干细胞(mesenchymal stem cells,MSCs)有着免疫调节、分化成肝细胞、促进原位肝细胞再生和抑制肝星状细胞的激活等能力,所以利用MSCs开展细胞移植治疗具有非常广阔的前景。本文通过综述各类人的肝病动物模型和运用这些动物模型开展MSCs细胞移植治疗肝病的临床前研究的进展和意义,将为今后在MSCs开展临床治疗的广泛应用中提供安全性和有效性评价的科学依据。Chronic liver diseases can further develop to liver fibrosis and cirrhosis. Currently,there is no effective treatment except liver orthotopic transplantation at this point. The extreme shortage of liver organ source forced people to find alternative treatment strategies. Mesenchymal stem cells（ MSCs） have the abilities of immunomodulatory,hepatocyte differentiation,promotion of liver cells regeneration in situ and inhibiting the activation of hepatic stellate cells. Therefore,MSCs transplantation provides a very broad prospect for cell therapy. It is important to provide preclinical evaluation of the efficacy and safety before the application of cell therapy in clinical trials. The progress of various animal models of human liver diseasees and significance of using MSCs to treat liver diseases in preclincal studies based on these animal models were reviewed in this paper.

关 键 词：肝病动物模型 间充质干细胞 临床前研究 

分 类 号：Q95-33[生物学—动物学]